Lutetium Lu 177-PSMA-617

PreclinicalRadiopharmaceutical

UUniversity of California, San Francisco

Lutetium Lu 177-PSMA-617 is one of 17 small molecule programs targeting Castration-Resistant Prostate Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Castration-Resistant Prostate CarcinomaRecruiting

Castration-Resistant Prostate CarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

16 competitors in Castration-Resistant Prostate Carcinoma

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 2

3 2

Zytiga

Johnson & Johnson

Phase 2

2 3

Jevtana

Sanofi

Phase 2

2 4

Keytruda

Merck & Co.

Phase 2

1 5

Paraplatin

AAvyxa

Phase 2

3 6

Depo-Testosterone

AAzurity Pharmaceuticals

Phase 2

2 7

Zolinza

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 8

Vepesid

AAvyxa

Phase 2

1 9

Berzosertib

Merck & Co.

Phase 2

1 10

Valemetostat Tosylate

Daiichi Sankyo

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

PreclinicalRecruiting

Castration-Resistant Prostate Carcinoma

NCT05113537

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT03805594·43 enrolled

Castration-Resistant Prostate Carcinoma1 trial

Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy

Recruiting·VVadim S Koshkin·Preclinical·NCT05113537·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Lutetium Lu 177-PSMA-617. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lutetium Lu 177-PSMA-617 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lutetium Lu 177-PSMA-617. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Francisco company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Preclinical[1]
Company: UUniversity of California, San Francisco

Lutetium Lu 177-PSMA-617

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Prostate Cancer1 trial

Castration-Resistant Prostate Carcinoma1 trial

References

Drug Info

Quick Facts

Related News